| Company/Division name | Eli Lilly and Company |
| Parent company | Eli Lilly and Company |
| Type of work | Manufacturing |
| Reshoring category: | Nearshoring |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1,200 |
| City reshored to: | Carolina |
| State(s) reshored to: | PR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals; orforglipron |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Skilled workforce availability/training |
